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Objectives: To investigate human immunodeficiency virus (HIV) virologic suppression and
drug resistance among HIV-infected patients receiving first-line antiretroviral treatment
(ART) in hospitals while community care and outreach through local health workers in
Guangxi, China.
Design: This was a series of cross-sectional surveys from 2004 to 2012 in Guangxi,
supported by the Chinese National HIVDR Surveillance and Monitoring Network Working
Group.
Settings: Guangxi, China.
Methods: Demographic, ART, and laboratory data (CD4+ cell count, viral load, and drug
resistance) were analyzed. Factors associated with virologic suppression were identified
by logistic regression analysis.
Results: A total of 780 patients were included in this study. The median treatment
duration was 20.6months (IQR 6.6–35.9). Of 780 study participants, 95.4% of patients
(744/780) had HIV virologic suppression. Among these, of the 143 patients who were
infected through drug injection, only 10 (7.0%) experienced virologic failure, and the
overall prevalence of HIV drug resistance was 2.8% (22/789). Factors associated with
virologic suppression in the final multivariate models included self-reported missing doses
in the past month (compared to not missing doses in the past month, AOR=0.2,
95% CI: 0.1–0.6) and initial ART regimen without 3TC (compared to initial ART regimen
with 3TC, AOR=0.2, 95% CI: 0.1–0.4). Moreover, the trend chi-square test showed
that the proportion of virologic suppression increased over time from 2004 to 2012
(P=0.002).
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Conclusion: This study first demonstrated that HIV patients infected through various
transmission routes can achieve an excellent treatment outcome in hospitals at or above
the county level for free first-line ART in Guangxi. It is an important of ART education and
adherence to intervention for achieving better treatment outcomes.
Keywords: HIV, antiretroviral treatment, virologic suppression, drug resistance, China
INTRODUCTION
Highly active antiretroviral therapy (HAART) has led to a dra-
matic increase in sustained suppression of human immunodefi-
ciency virus (HIV) replication. Since HAART was developed in
the early 1990s, there has been a rapid improvement in prognosis
of patients infected with HIV and reduction in AIDS-related
mortality (1, 2). In resource-rich countries, because of the use of
optimal regimens and a complete monitoring system for virologic
failure anddrug resistance, levels of drug resistance decreased over
time (3, 4). As a result of the scale-up of the “3 by 5” project in
low-income and middle-income countries, an increasing number
of patients received antiretroviral treatment (ART) from 2003.
However, the emergence of HIV drug resistance (HIVDR) was a
big challenge to the rapid development of HAART (5, 6).
The China’s National Free Antiretroviral Treatment Program
(NFATP) began in 2002 and rapidly scaled-up. In 2008, China’s
NFATP changed the threshold of initiating free ART access to
more patients (7). By the end of 2013, among the 436,817 people
living with HIV in China, the total number receiving free ART
had increased to 278,080 (8). In China, ART has significantly
reduced mortality among HIV patients (9–11) and HIV trans-
mission among serodiscordant couples in the Chinese national
observational cohort study (12). However, meta-analysis study
results showed that the pooled prevalence of HIVDR was 11.1%
during 0–12months and increased to 22.92% at 61–72months in
Chinese HIV-Infected Patients Receiving First-Line HAART (13).
Guangxi Zhuang Autonomous Region located on the southern
coast of the China, and neighboring Vietnam in the South and
Yunnan Province in the west, is the major drug trafficking route
linking Guangxi with Yunnan and Vietnam. The reported cases
of HIV/AIDS in Guangxi accounted for 10% of the reported
numbers in China. The first HIV infection among local IDUs
was observed in 1996 in Guangxi, and HIV infection through
drug injection accounted for 69% of the cumulative reported
cases of HIV in Guangxi in 2003 (14). However, in 2013, 93%
of reported HIV cases in Guangxi were infected through hetero-
sexual intercourse (15). Guangxi ZhuangAutonomous Region has
the highest number of reported HIV cases in China (15). Because
of the capacity in county hospital-based care and management
for free ART in Guangxi, the aim of this study was to evaluate
virologic failure and drug resistance and associated factors among
HIV-infected patients receiving first-line ART.
MATERIALS AND METHODS
Study Design and Study Participants
We conducted a series of cross-sectional surveys of HIVDR
in adult patients at regional representative ART clinics in
Guangxi from 2004 to 2012. This protocol of Chinese National
HIVDR Surveillance was adopted from the WHO recommended
cross-sectional survey on acquired HIVDR in adult patients
receivingART,which has been described elsewhere (16–19). First-
line ART regimens before 2008 consisted of [azidothymidine
(AZT) or stavudine (D4T)]+ [didanosine (DDI) or lamivu-
dine (3TC)]+ [nevirapine (NVP) or efavirenz (EFV)]. The sec-
ond edition of the National Free ART Guideline in 2008
was revised to consist of [tenofovir (TDF) or azidothymidine
(AZT)]+ lamivudine (3TC)+ [efavirenz (EFV) or nevirapine
(NVP)] (7). The NFATP criterion for treatment was (1) CD4
cell count <200/mm3 before 2008, and <350/mm3 since 2008,
(2) total lymphocyte count <1200/mm3 before 2008, and/or (3)
WHO stage III or IV disease (7, 20). The study eligibility criteria
were HIV patients, 18 years or older, having received first-line
ART, willingness and consent to participate in the study. Patients
who received second-line ART were excluded.
Data Collection
The data were collected with an interviewer-administered ques-
tionnaire. Each participant provided informed consent before
participation in the study. Each subject was assigned a confi-
dential identification number to label questionnaires and blood
specimens. The questionnaire was administered by trained local
staff in a private room. The questionnaire information included
demographic data, HAART treatment, and self-reported adher-
ence measures. Demographic variables included sex, ethnicity,
education level, occupation, marital status, and HIV transmis-
sion route. HAART treatment variables included initial regimen,
the duration of HAART, and end of HAART regimen. Self-
reported adherence variables included missed ART doses in the
past month. The institutional review board (IRB) of the National
Center on HIV/STD Control and Prevention (NCAIDS), China
CDC approved this study.
Laboratory Analysis
Blood specimens were provided by all subjects to determine
CD4+ T-lymphocyte count (CD4 count), HIV viral load (VL),
and HIVDR mutations. The CD4 count was determined by flow
cytometry within 24 h after collection in the provincial CDC.
The Plasma HIV RNA was quantified with real-time NASBA
(NucliSense Easy Q, bioMerieux, France) or COBAS (Roche
Applied Biosystems, Germany) according to the manufacturer
recommendations. In samples with a viral load 1000 copies/ml,
HIVDR was determined by using an in-house polymerase chain
reaction (PCR) (16, 21). The Stanford HIV Drug Resistance
Database (http://hivdb.stanford.edu/) was used to analyze drug
resistance mutation and viral subtype determination. Low-,
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intermediate-, and high-level drug resistance were defined as
HIVDR (22, 23).
Data Analysis
Questionnaire and laboratory data were double entered and com-
pared with Epidata 3.1 (The Epidata Association Odense, Den-
mark), and then were analyzed by Statistical Analysis System (SAS
9.2, SAS Institute Inc., Cary, NC, USA). Demographic variables
were described with descriptive statistics. Factors associated with
virologic failure (viral load 1000 copies/ml) were identified by
univariate and multivariate logistic regression models. Variables
with P< 0.05 were retained in multivariate logistic regression
models using stepwise selection and results were presented with
adjusted odds ratio (AOR) and 95% CIs. Hypothesis testing was
two-sided with α= 0.05.
RESULTS
Demographic Characteristics
Seven hundred eighty patients were included in this study.
Among these, 221 patients were investigated in 2004–2006, 114
patients were investigated in 2006–2007, and then 291 patients
were surveyed in 2007–2009, whereas 154 patients were included
in 2011–2012. The demographic characteristics of the subjects
are shown in Table 1. Among the patients, the mean age was
39.2 12.2 years, 61.9% were male, 87.1% belonged to the Han
ethnic group, 21.9% had an education level of high school or
higher, 76.9% were primarily farmers, and 23.2% were married.
Reported transmission routes were 75.3% sexual transmission,
18.3% injection drug use, 1.4% blood transmission, and 5.0%
other.
HAART Regimens and Virologic Profiles
Initial HAART regimens used were AZT+ 3TC+EFV
(12.2%), AZT+ 3TC+NVP (32.1%), D4T+ 3TC+EFV
(5.1%), D4T+ 3TC+NVP (34.7%), and DDI-based regimens
(15.9%). The median of the duration of ART was 20.6months.
At the time of the survey, 36 (4.6%) patients had a viral load
1000 copies/ml. Among these subjects, 35 were successfully
genotyped. CRF01_AE was the most common HIV viral subtype
(31/35, 88.5%). Of these, 22 had detectable HIVDR mutations.
HIV Drug Resistance Mutations
Among the 35 subjects successfully genotyped with viral load
1000 copies/ml, 22 patients were identified with HIVDR muta-
tions, and the overall prevalence of HIVDR was 2.8% (22/789)
among HIV-infected patients receiving first-line ART. Approxi-
mately 54.5% (12/22) of patients were resistant to non-nucleoside
reverse transcriptase inhibitor (NNRTIs) drugs, 90.9% (20/22)
of patients were resistant to nucleoside reverse transcriptase
inhibitor (NRTIs) drugs, and 4.5% (1/22) of patients had drug
resistance to protease inhibitors (PIs). In addition, 45.5% (10/22)
of patients were identified as multi-drug resistance to NNRTIs
and NRTIs. The most frequent NNRTIs mutations occurred at
position 101 in the RT (reverse transcriptase) region, NRTIs
mutations occurred at position 184 in the RT region, and PI
TABLE 1 |Characteristics of HIV patients receiving first-line ART in Guangxi.
Characteristics Number Percentage
Total 780
Age (years): meanSD 39.212.2
Sex
Male 483 61.9
Female 297 38.1
Ethnicity
Han 679 87.1
Minorities 101 12.9
Education
Illiterate 33 4.2
Primary school 236 30.3
Junior high school 340 43.6
High school or more 171 21.9
Occupation
Others 180 23.1
Farmer 600 76.9
Married
Yes 181 23.2
No 599 76.8
HIV transmission route
Sexual intercourse 587 75.3
Drug injection 143 18.3
Blood transfusion 11 1.4
Others 39 5.0
CD4 count before ART (cells/mm3)
350 10 1.3
349–200 116 14.9
199–100 142 18.2
<100 512 65.6
Missed doses in the past month
No 757 97.9
Yes 23 2.1
Duration of ART (months): median, IQR 20.6 6.6–35.9
Initial ART regimen
AZT+ 3TC+EFV 95 12.2
AZT+ 3TC+NVP 250 32.1
D4T+ 3TC+EFV 40 5.1
D4T+ 3TC+NVP 271 34.7
DDI-based regimens 124 15.9
mutations occurred at position 84 in the PR (protease) region
(Table 2).
Predictors for HIV Virologic Suppression
Of 780 study participants, 744 (95.4%) hadHIV virologic suppres-
sion. Univariate logistic regression models were used to examine
the factors associated with HIV virologic suppression (Table 3).
Ethnicity, initial ART regimen, and missed doses in the past
month were associated with virologic suppression. Those found
to be statistically significant were included in the multivariate
logistic regression model. Factors associated with virologic sup-
pression in the final multivariate models include self-reported
missing doses in the past month (compared to not missing doses
in the past month, AOR= 0.2, 95% CI: 0.1–0.6) and initial ART
regimen without 3TC (compared to initial ART regimen with
3TC, AOR= 0.2, 95%CI: 0.1–0.4).Moreover, the trend chi-square
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TABLE 2 | HIV drug resistance mutations among HIV patients receiving
first-line ART in Guangxi.
Antiretroviral drug N (%) HIV drug resistance
mutations, N (%)
Total 22 (100.0)
Non-nucleoside reverse
transcriptase inhibitors (NNRTI, any)
12 (54.5) K101E/EK/H/P, 4 (18.2)
Efavirenz (EFV)a 12 (54.5) K103N/KN/S, 3 (13.6)
Nevirapine (NVP)a 12 (54.5) V106L/I, 2 (9.1)
Delavirdine (DLV) 11 (50.0) G190A, 2 (9.1)
Etravirine (ETV) 2 (9.1) Y181C/I, 2 (9.1)
E138EQ, 1 (4.5)
Y188L, 1 (4.5)
Nucleoside reverse transcriptase
inhibitors (NRTI, any)
20 (90.9)
Emtricitabine (FTC) 18 (81.8) M184V/MV, 8 (36.4)
Lamivudine (3TC)a 18 (81.8) T69I/IN/N, 6 (27.3)
Abacavir (ABC) 15 (68.2) D67DG/DN/G/N, 4 (18.2)
Didanosine (DDI)a 17 (77.3) L74V, 2 (9.1)
Stavudine (D4T)a 14 (63.6) M41I/LM, 2 (9.1)
Tenofovir (TDF)a 8 (36.4) K65R, 1 (4.5)
Azidothymidine (AZT)a 12 (54.5) V75T, 1 (4.5)
L210M, 1 (4.5)
F116Y, 1 (4.5)
T215Y, 1 (4.5)
K70KR, 1 (4.5)
F215FIST, 1 (4.5)
Protease inhibitors (PI, any) 1 (4.5)
Tipranavir (TPV) 1 (4.5) I84IV, 1 (4.5)
Fosamprenavir (FPV) 1 (4.5)
Lopinavir (LPV)a 0 (0.0)
Nelfinavir (NFV) 1 (4.5)
Atazanavir (ATV) 1 (4.5)
Darunavir (DRV) 0 (0.0)
Indinavir (IDV) 1 (4.5)
Saquinavir (SQV) 1 (4.5)
Multi-drug resistance to NNRTI and
NRTI
10 (45.5)
aProvided through the National Free Antiretroviral Treatment Program (NFATP).
test showed that the proportion of virologic suppression increased
over time from 2004 to 2012 (P= 0.002).
DISCUSSION
In this study, we found significant low virologic failure (4.6%)
and drug resistance (2.8%) amongHIV-infected patients receiving
first-line ART with the median duration of treatment of about 20-
month in Guangxi, China. Also, virologic suppression increased
over time. A recent systematic review and meta-analysis showed
that the pooled prevalence of HIVDR was 11.1% (95% CI,
7.49–16.14%), which increased to 22.92% at 61–72months (95%
CI, 9.45–45.86%) among Chinese HIV-infected patients receiv-
ing first-line ART in China (13). Defining 1000 copies/ml as the
same threshold of virologic failure, a systematic review conducted
in Sub-Saharan Africa concluded that the rate of virologic sup-
pression were 76 and 67% with the median duration of ART
at 12- and 24-month, respectively (24). Based on another sys-
tematic review conducted in resource-limited settings in 2013,
HIVDR at 12–23months was 11.1% (25). With prolonged treat-
ment, the rate of virologic failure and drug resistance increased
over time (26, 27). In the 2012 WHO drug resistance surveillance
guideline, viral load suppression after 12months of ART can
be graded as poor (<70%), fair (70–85%), or excellent (>85%)
(28). The prevalence of virologic failure and drug resistance in
our study is comparable to the virologic treatment responses
seen in other developed and industrialized countries (4). What
is more, of the 143 patients who were infected by drug injection,
only 10 (7.0%) experienced virologic failure, lower than other
provinces in China and this result consist with previous study
in China (19). Compared to those results, we can conclude that
successful outcomes of ART can be achieved in resource-limited
settings.
There are several reasons to explain low virologic failure and
drug resistance among HIV-infected patients receiving first-line
ART in Guangxi. First, there are three levels of AIDS hospitals
providing ART for HIV patients, including provincial, prefecture,
and county hospitals. One provincial hospital provides technical
supports and training to each prefecture hospital, which then
provides technical assistance to each county hospital. Second,
although HIV patients receive treatment in hospitals at or above
the county level, health staff at village clinics or township hospitals
are responsible for community care and outreach, such as home
visits or telephone calls for reminding of ART adherence, and
making an appointment if patients did not see doctors at AIDS
hospitals for ART management every 3-month follow-up. Third,
all doctors and health staff for ART and care management receive
comprehensive HIV/AIDS medical training. Fourth, initial ART
regimen with 3TC can increase virologic suppression. Our pre-
vious studies found HIV patients who received ART at village
clinics, township hospitals, or local CDCs had poor virologic
outcomes, whereas treatment counseling and instruction through
telephone and 3TC-based regiments were significantly associated
with HIV RNA suppression (16, 29, 30).
Despite successful HIV virologic suppression in this study,
patients with missed doses in the past month and initial ART
regiments without 3TCwere found to be at increased risk for poor
virologic response. This indicates that measures should be con-
tinuously taken to train local medical staff, and educate patients
and enhance adherence monitoring. Due to the poor outcome of
patients that receivedDDI-based treatment, theNFATP’s first-line
antiretroviral regimens have been changed to exclude the use of
didanosine (DDI) and to include the use of lamivudine (3TC) for
all new patients beginning treatment since 2008 (7).
The prevalence of HIVDR among patients who experienced
virologic failure was 62.9% (22/35). Of 22 patients with HIVDR,
the proportions of NNRTI mutations, NRTI mutations, and PI
mutations were 54.5, 90.0, and 4.5%, respectively. In addition, 10
(45.5%) were identified to be resistant to multi-drugs. M184I/V
was themost commonNRTImutations and other studies inChina
showed similar results (16, 29). One PI mutation was identified in
this study, because that PI was not scaled-up at that period.
The limitations can be summedup as follows. First, these results
may not represent all patients in Guangxi because of the exclusion
criteria and limited geographic distribution of the surveillance
sites. Also, the surveys did not include all patients who have met
the inclusion criteria in Guangxi, so when we draw the conclusion
we should be cautious. Second, considering diverse HIV epidemic
conditions in different districts in Guangxi, the difference among
those districts should be considered.
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TABLE 3 | Factors associated with HIV viral suppression (viral load <1000copies/ml) among HIV patients receiving first-line ART in Guangxi.
Variable Number Viral suppression Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
N (%)
780 744 (95.4)
Age (years)
<40 486 458 (94.2)
40 294 286 (97.3) 2.2 (0.9, 4.9) 0.06
Sex
Male 483 459 (95.0)
Female 297 285 (96.0) 1.2 (0.6, 2.5) 0.55
Ethnicity
Han 679 652 (96.0)
Minorities 101 92 (91.1) 0.4 (0.2, 0.9) 0.03
Education
High school or more 269 261 (97.0)
Junior high school or less 511 483 (94.5) 0.5 (0.2, 1.8) 0.12
Occupation
Others 180 175 (97.2)
Farmer 600 569 (94.8) 1.9 (0.7, 4.9) 0.19
Married
No 181 170 (93.9)
Yes 599 574 (95.8) 1.5 (0.7, 3.1) 0.29
CD4 cell counts before ART
200 126 123 (97.6)
<200 654 621 (96.3) 0.5 (0.1, 1.5) 0.20
Initial ART regimen
Regimens with 3TC 656 638 (97.3)
Regimens without 3TC 124 106 (85.5) 0.2 (0.1, 0.3) <0.0001 0.2 (0.1, 0.4) <0.0001
HIV transmission route
Drug injection 143 133 (93.0)
Others 637 611 (96.0) 1.8 (0.8, 3.8) 0.14
Missed doses in the past month
No 757 726 (95.9)
Yes 23 18 (78.3) 0.2 (0.1, 0.4) <0.001 0.2 (0.1, 0.6) 0.003
Time of starting ART (years)
Before 2006 182 165 (90.7)
2006–2008 339 327 (96.5) 2.8 (1.3, 6.0) 0.008
After 2008 259 252 (97.3) 3.7 (1.5, 9.1) 0.004
In summary, this study in Guangxi demonstrates that HIV-
infected patients receiving first-line treatment achieve an excellent
treatment outcome andwe can summarize those factors associated
with virologic suppression as increasing the proper use of 3TC-
based regimens and strengthening the importance of adhering to
treatment.
CONCLUSION
In this study, we found significant low virologic failure and drug
resistance among HIV-infected patients receiving first-line ART
with the median duration of treatment of about 20-month in
Guangxi, China. Our study demonstrated that HIV-infected
patients receiving first-line treatment can achieve an excellent
treatment outcome in hospitals at or above the county level for
free ART in Guangxi, and we can conclude that the increasing
the proper use of 3TC-based regimens and the strengthening the
importance of adhering to treatment are associated with virologic
suppression.
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